Medicus Pharma Ltd. announced its financial and operating results for the quarter ending September 30, 2025.
Key highlights include progress in clinical development programs for SKNJCT-003 and SKNJCT-004 focusing on non-invasive treatments for basal cell carcinoma.
The company also expanded its SkinJect platform and acquired Antev Limited for pipeline expansion.
Clinical Development Progress
Progress in Phase 2 clinical studies for SKNJCT-003 and SKNJCT-004 for non-invasive treatments.
Pipeline Expansion
Acquisition of Antev Limited and development of Teverelix, a next generation GnRH antagonist.
Patient Access Collaboration
Collaboration with Gorlin Syndrome Alliance for compassionate access to SkinJect.
- The FDA feedback on the Type C meeting supporting the development of SkinJect marks a significant milestone in Medicus Pharma's clinical programs.
- The acquisition of Antev and the introduction of Teverelix offer promising potential for the company's pipeline expansion.
Medicus Pharma Ltd. continues to make significant strides in advancing innovative therapeutic assets and expanding patient access through strategic collaborations.